Epify BV
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Epify BV - overview
Established
2019
Location
Maastricht, -, Netherlands
Primary Industry
Biotechnology
About
Based in Limburg, Netherlands, and founded in 2019, Epify BV is a company that focuses on facilitating cancer diagnosis and personalized treatments through epigenetic biomarkers. The company was founded by Manon van Engeland and Wim van Criekinge. In September 2019, Epify BV raised EUR 0. 5 million in seed funding from investors Brightlands Venture Partners and Novalis Biotech.
The company specializes in the development of epigenetic biomarkers that regulate gene activity and are associated with various types of cancer. These biomarkers have been the focus of efforts to enable less invasive cancer detection and early intervention. Epify's goal is to leverage these biomarkers for earlier and more precise detection, enabling personalized oncology and offering improved prospects for cancer patients.
Current Investors
Brightlands Venture Partners, Novalis Biotech
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals
Website
www.epify.nl/
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Epify BV - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.